These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31939069)

  • 1. Effect of Dolutegravir and Sertraline on the Blood Brain Barrier (BBB).
    Ma Q; Schifitto G; Venuto C; Ocque A; Dewhurst S; Morse GD; Aalinkeel R; Schwartz SA; Mahajan SD
    J Neuroimmune Pharmacol; 2020 Mar; 15(1):7-9. PubMed ID: 31939069
    [No Abstract]   [Full Text] [Related]  

  • 2. Mutations in the HIV-1 3'-Polypurine Tract Can Confer Dolutegravir Resistance.
    Dekker JG; Klaver B; Berkhout B; Das AT
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0102721. PubMed ID: 34633840
    [No Abstract]   [Full Text] [Related]  

  • 3. The promise of paediatric dolutegravir.
    Golin R; Samuel JM; Phelps BR; Persaud U; Malati CY; Siberry GK
    J Int AIDS Soc; 2021 Jan; 24(1):e25660. PubMed ID: 33522081
    [No Abstract]   [Full Text] [Related]  

  • 4. Antiretroviral drug dolutegravir induces inflammation at the mouse brain barriers.
    Huang C; Hoque MT; Qu QR; Henderson J; Bendayan R
    FASEB J; 2024 Jul; 38(13):e23790. PubMed ID: 38982638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.
    Tzou PL; Rhee SY; Descamps D; Clutter DS; Hare B; Mor O; Grude M; Parkin N; Jordan MR; Bertagnolio S; Schapiro JM; Harrigan PR; Geretti AM; Marcelin AG; Shafer RW;
    J Antimicrob Chemother; 2020 Jan; 75(1):170-182. PubMed ID: 31617907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 diversity and the implementation of integrase strand-transfer inhibitors as part of combination antiretroviral therapy.
    Mikasi SG; Ikomey GM; Obasa AE; Cloete R; Jacobs GB
    S Afr Med J; 2020 Aug; 110(9):13071. PubMed ID: 32880259
    [No Abstract]   [Full Text] [Related]  

  • 7. Dolutegravir drug-resistance monitoring in Africa.
    Kouamou V; Inzaule S; Manasa J
    Lancet HIV; 2021 Nov; 8(11):e664-e666. PubMed ID: 34735801
    [No Abstract]   [Full Text] [Related]  

  • 8. Dosing of Dolutegravir in TB/HIV Coinfected Patients on Rifampicin: Twice Is (Always) Better Than Once.
    Cattaneo D; Riva A; Columpsi P; Lapadula G; Filice C; Gervasoni C
    J Acquir Immune Defic Syndr; 2020 Jul; 84(3):e17-e20. PubMed ID: 32205722
    [No Abstract]   [Full Text] [Related]  

  • 9. High performance of integrase genotyping on diverse HIV-1 clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in low and middle-income countries.
    Fokam J; Ngoufack Jagni Semengue E; Armenia D; Takou D; Dambaya B; Teto G; Chenwi CA; Nka AD; Beloumou GA; Ndjeyep SCD; Tchouaket MCT; Fainguem N; Sosso SM; Colizzi V; Perno CF; Ndjolo A; Ceccherini-Silberstein F; Santoro MM
    Diagn Microbiol Infect Dis; 2022 Feb; 102(2):115574. PubMed ID: 34864527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-level dolutegravir resistance can emerge rapidly from few variants and spread by recombination: implications for INSTI salvage therapy.
    Duarte FC; Moura LM; Laranjinha J
    AIDS; 2022 Nov; 36(13):1881-1882. PubMed ID: 36172870
    [No Abstract]   [Full Text] [Related]  

  • 11. Increase in visceral adipose tissue in a woman living with HIV after introduction of integrase strand transfer inhibitor.
    Piacentini D; Lanzafame M; Rizzardo S; Chiesi S; Lattuada E; Mehrabi S; Zamboni G; Mazzi R; Tacconelli E; Vento S
    Int J STD AIDS; 2020 Dec; 31(14):1407-1410. PubMed ID: 33081650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is resistance to dolutegravir possible when this drug is used in first-line therapy?
    Mesplède T; Wainberg MA
    Viruses; 2014 Aug; 6(9):3377-85. PubMed ID: 25166745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compelling evidence for unconditional shift to dolutegravir.
    Steegen K; Hans L
    Lancet HIV; 2022 Aug; 9(8):e523-e524. PubMed ID: 35905750
    [No Abstract]   [Full Text] [Related]  

  • 14. Dolutegravir for children with HIV-associated tuberculosis.
    Meyers T; Krogstad P
    Lancet HIV; 2022 Sep; 9(9):e599-e600. PubMed ID: 35868340
    [No Abstract]   [Full Text] [Related]  

  • 15. Reverse transcription of HIV-1 2-LTR circle transcripts does frequently cause 3'-polypurine tract mutations implicated in dolutegravir resistance.
    Dekker JG; Klaver B; Berkhout B; Das AT
    J Virol; 2024 Jun; 98(6):e0033524. PubMed ID: 38785421
    [No Abstract]   [Full Text] [Related]  

  • 16. Body Fat Distribution and Metabolic Changes in a Cohort of Adolescents Living With HIV Switched to an Antiretroviral Regimen Containing Dolutegravir.
    Giacomet V; Lazzarin S; Manzo A; Paradiso L; Maruca K; Barera G; Zuccotti GV; Mora S
    Pediatr Infect Dis J; 2021 May; 40(5):457-459. PubMed ID: 33847293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalent polymorphisms in wild-type HIV-1 integrase are unlikely to engender drug resistance to dolutegravir (S/GSK1349572).
    Vavro C; Hasan S; Madsen H; Horton J; DeAnda F; Martin-Carpenter L; Sato A; Cuffe R; Chen S; Underwood M; Nichols G
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1379-84. PubMed ID: 23295935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy.
    Chen GJ; Sun HY; Chang SY; Cheng A; Huang YS; Huang SH; Huang YC; Su YC; Liu WC; Hung CC
    Int J Infect Dis; 2021 Apr; 105():147-151. PubMed ID: 33592339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Barrier to Resistance of Dolutegravir in Two-Drug Combinations.
    Yoshinaga T; Miki S; Kawauchi-Miki S; Seki T; Fujiwara T
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30602514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling.
    Liu XI; Momper JD; Rakhmanina NY; Green DJ; Burckart GJ; Cressey TR; Mirochnick M; Best BM; van den Anker JN; Dallmann A
    Clin Pharmacokinet; 2020 Nov; 59(11):1433-1450. PubMed ID: 32451908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.